Drug-discovery scientists work with microbiology, clinical, formulation and commercial specialists to turn early antimicrobial signals into a disciplined animal-health programme.
Dr Md Arif Sheikh leads biology, formulation and drug discovery. Dr David Brown contributes more than 50 years of pharmaceutical R&D experience. Together, they guide scientific development and commercial judgement.
Scientific architect of Green Antibiotics, with more than 20 years across microbiology, molecular and structural biology, cancer research and drug discovery. He leads screening, evidence strategy, IP and programme execution.
Drug discoverer and scientific adviser with more than 50 years across global pharmaceutical R&D. He brings screening discipline, development strategy and independent scientific judgement to Green Antibiotics.
The wider AVIX team supports microbiology, formulation, clinical coordination, manufacturing readiness, communication and commercial preparation wherever Green Antibiotics needs those capabilities.
Scientific judgement, validation planning, product execution and commercial discipline need to progress together.
Compound selection, microbiology and screening interpretation progress together.
MIC/MBC, safety, stability and controlled target-animal validation planning.
Formulation, analytical control, supplier coordination and scalable production.
Investment, partnerships, regulatory routes and disciplined commercial translation.
